# A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT05929066
- Published: 2023-07-03
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05929066
- Source URL: https://clinicaltrials.gov/study/NCT05929066
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: TRIUMPH-1
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 2335
- sponsor: Eli Lilly and Company
- conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea
- interventions: DRUG: Retatrutide; DRUG: Placebo
- start date: 2023-07-10
- start date type: ACTUAL
- primary completion date: 2026-04-06
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.